Business Wire

NY-AQARA

23.3.2023 09:01:30 CET | Business Wire | Press release

Share
Aqara Releases Video Doorbell G4 with Facial Recognition to Global Markets

Aqara, a leading provider of smart home products, announces the wide availability of the Company’s first smart video doorbell, the G4, on global markets. This 1080p doorbell features wide compatibility with third-party smart home platforms such as Apple Home, Alexa and Google Home, and it is equipped with on-device AI to enable local facial recognition alerts and automation. Together with the Company’s indoor cameras, the video doorbell G4 helps users keep an eye on their homes, families and visitors anytime, anywhere. The device is now available on Aqara’s Amazon brand stores in both North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK) as well as via selective Aqara retailers worldwide1.

Similar to Aqara’s Camera Hub G3, the Aqara Smart Video Doorbell G4 features AI-based facial recognition, which is executed locally on device for faster response and privacy protection. Moreover, facial recognition of the doorbell can be used as an automation trigger, allowing users to set up customized home automation for different families and visitors. For example, the welcome home scene will be activated when the G4 recognizes a family member coming home. Or in the case that it detects the postman, the doorbell will play a pre-recorded message. When connected to other Aqara devices, the G4 doorbell can also be a strong addition to the Aqara Home alert system as it not only monitors the activities around the front porch but also lets out a loud siren in case of home intrusion and other emergencies.

Apart from the Aqara ecosystem, the G4 doorbell also supports major third-party smart home platforms including Apple Home, Amazon Alexa and Google Home. This device is one of the few battery-powered video doorbells on the market that support Apple’s HomeKit Secure Video as well as the local streaming to Amazon and Google smart displays. Moreover, Aqara anticipates adding the support of the new Matter standard to the G4 via a future OTA (over the air) update2.

With two color variants, Shadow Gray and Black, the video doorbell G4 is designed to fit into most home environments. It supports both wireless and wired installation and can use a pack of 6 AA batteries that lasts about 4 months3. The doorbell offers adjustable sensitivity, configurable motion detection and even a power saving mode for users who live in a high traffic area to extend the battery life. Alternatively, users can opt to wire the G4 doorbell to an AC/DC transformer for 24/7 recording4, and use the battery pack as a back-up power source. Additionally, the G4’s chime repeater, which is equipped with a 95 dB speaker, houses a Type-C port, and allows more flexibility for users to place the chime repeater indoors.

Users of the Video Doorbell G4 can store video footage locally or on the cloud via iCloud or Aqara platform5. Aqara offers a subscription-free cloud storage of up to 7 days of critical event clips such as motion detection, facial recognition, doorbell ring and tamper alerts. Users can also choose to save video footage locally using a microSD card (up to 512 GB)6, which is housed in the indoor chime repeater. Finally, videos can also be stored via SMB NAS for added flexibility and security7.

For more details of the G4 video doorbell, please visit our website.

  1. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
  2. Matter support is not available by the time of launch.
  3. Based on assumption of 35 device wake-ups and one 6-second event video recording per day. The actual battery life may vary, depending on multiple factors including device usage, battery capacity, ambient temperature, etc.
  4. A 12-24V AC or 8-24V DC transformer is required. Both a wired installation and the use of a microSD card are required for 24/7 recording.
  5. iCloud or other supported cloud storage is not included, and should be controlled separately via the respecting app.
  6. The microSD card is not included.
  7. SMB NAS support may be unavailable by the time of product launch.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005016/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye